BR112022005412A2 - Composições nanoparticuladas para terapia gênica - Google Patents

Composições nanoparticuladas para terapia gênica

Info

Publication number
BR112022005412A2
BR112022005412A2 BR112022005412A BR112022005412A BR112022005412A2 BR 112022005412 A2 BR112022005412 A2 BR 112022005412A2 BR 112022005412 A BR112022005412 A BR 112022005412A BR 112022005412 A BR112022005412 A BR 112022005412A BR 112022005412 A2 BR112022005412 A2 BR 112022005412A2
Authority
BR
Brazil
Prior art keywords
gene
gene therapy
nanoparticulate compositions
knock
mutation
Prior art date
Application number
BR112022005412A
Other languages
English (en)
Inventor
Irene Lara-Saez
O'keeffe Ahern Jonathan
Qian Xu
Sigen A
Wenxin Wang
Original Assignee
Univ Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dublin filed Critical Univ Dublin
Publication of BR112022005412A2 publication Critical patent/BR112022005412A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Mycology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

composições nanoparticuladas para terapia gênica. uma composição nanoparticulada compreende um sistema de ribonucleoproteína de edição gênica complexado dentro de um polímero catiônico. o polímero catiônico pode ser um polímero hiperramificado de poli-beta amino éster, especialmente um polímero hiperramificado de 4 ramificações. o sistema de ribonucleoproteína de edição gênica pode ser um sistema de edição gênica crispr-cas9 configurado para excisar uma mutação ou éxon em um gene, substituir uma mutação em um gene ou produzir um knock-down ou knock-out de um gene e, em particular, configurado para excisar o éxon 80 do gene col7a1 que codifica para a proteína de colágeno vii. os dados mostram tal uso.
BR112022005412A 2019-09-25 2020-09-22 Composições nanoparticuladas para terapia gênica BR112022005412A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19199697 2019-09-25
PCT/EP2020/076449 WO2021058492A1 (en) 2019-09-25 2020-09-22 Nanoparticle compositions for gene therapy

Publications (1)

Publication Number Publication Date
BR112022005412A2 true BR112022005412A2 (pt) 2022-06-21

Family

ID=68208251

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005412A BR112022005412A2 (pt) 2019-09-25 2020-09-22 Composições nanoparticuladas para terapia gênica

Country Status (7)

Country Link
US (1) US20220340933A1 (pt)
EP (1) EP4034152A1 (pt)
CN (1) CN114650811A (pt)
AU (1) AU2020353221A1 (pt)
BR (1) BR112022005412A2 (pt)
CA (1) CA3151988A1 (pt)
WO (1) WO2021058492A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023131648A1 (en) 2022-01-05 2023-07-13 Branca Bunus Limited Nanoparticulate compositions for gene therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CN1832755A (zh) 2003-05-23 2006-09-13 佩斯特卡生物医疗实验室公司 使用干扰素治疗严重急性呼吸综合征及其他病毒感染
US20070053845A1 (en) 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
US8105572B2 (en) 2007-05-18 2012-01-31 New York University Method of treating tuberculosis with interferons
EP2050437A1 (en) 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
WO2014033644A2 (en) 2012-08-28 2014-03-06 Novartis Ag Methods of nuclease-based genetic engineering
GB201413907D0 (en) 2014-08-06 2014-09-17 Nat Univ Ireland Hyberbranched poly(beta-amino ester) for gene therapy
US10253365B1 (en) 2017-11-22 2019-04-09 The Regents Of The University Of California Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs

Also Published As

Publication number Publication date
US20220340933A1 (en) 2022-10-27
CN114650811A (zh) 2022-06-21
CA3151988A1 (en) 2021-04-01
WO2021058492A1 (en) 2021-04-01
AU2020353221A1 (en) 2022-03-31
EP4034152A1 (en) 2022-08-03

Similar Documents

Publication Publication Date Title
CY1120507T1 (el) Συνεργιστικη ενισχυση της διανομης νουκλεϊκων οξεων μεσω συμμειγμενων σκευασματων
CO6470863A2 (es) Mutantes fgf21 y usos de los mismos
MX2022003414A (es) Celulas efectoras con multiples objetivos y uso de las mismas.
BRPI0923855A8 (pt) Ácido lipóico, e, composição de ração de animal de estimação
BR112013003825A2 (pt) conjugados, partículas, composições e métodos relacionados
BR112013003722A2 (pt) produtos para cuidado e métodos de uso e fabricação dos mesmos
BR112013010855A2 (pt) luciferases derivadas de oplophorus, novos substratos de coelenterazina e métodos de uso
BR112022005412A2 (pt) Composições nanoparticuladas para terapia gênica
ES2534303T3 (es) Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
BR112012032742A2 (pt) composições líquidas não aquosas estáveis compreendendo um polímero catiônico sob a forma de particulado
BR112018015291A2 (pt) uso de inibidores de histona desacetilase para melhorar imunoterapias
CL2020001821A1 (es) Formulación de adenovirus del grupo b.
ES2616017T3 (es) Composiciones que contienen sulfato de condroitina, nattocinasa y compuestos de sulfhidrilo para su uso en el tratamiento de inflamación
BR112018010945A2 (pt) formulações com degradação de polissorbato reduzida
BR112014012726A2 (pt) composições de cuidado dos cabelos
BR112017023472A2 (pt) partícula de fornecimento de agente benéfico, composição e processo de produção de partículas
BR112017028576A2 (pt) composições de corantes e seus métodos de uso
BR112015012957B8 (pt) composição de cuidado oral e uso de aminoácido básico, sistema conservante e carbonato de cálcio no preparo da referida composição
MY193776A (en) Modified cytotoxins and their therapeutics use
BR112012022683A2 (pt) agente de cura para resinas epóxi, formulação de resina epóxi à base de água, uso das formulações de resina epóxi à base de água, composição de tinta ou de revestimento, produtos curados, e, método para preparar um agente de cura
BR112019003816A2 (pt) composição de tratamento de enxágue dos cabelos, método para tratamento de cabelos quimicamente danificados e uso de uma composição
BR112015022484A2 (pt) formulações com oxidação reduzida
BR112012022073A2 (pt) uso de meloxicam para o tratamento de longa duração de distúrbios musculoesqueletais em gatos.
BR112015032669A2 (pt) composição, uso de pelo menos um pigmento revestido e método de cuidado cosmético
BR112022004563A2 (pt) Coliberação de sirna tgf-ß e sirna pdl1 para tratar câncer